NCT02629757

A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas

A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to help determine whether β-elemene as maintain treatment for complete remission patients of newly diagnosed malignant gliomas following standard treatment, is able to delay tumor growth, or impact how long people with newly diagnosed high-grade glioma.

Detailed description

This study is being conducted to help determine whether β-elemene as maintain treatment for complete remission patients of newly diagnosed malignant gliomas following standard treatment, is able to delay tumor growth, or impact how long people with newly diagnosed high-grade glioma. β-elemene will be given 600mg/d,d1-14,q28 days for 6 cycles.

Conditions

• Anaplastic Oligoastrocytoma
• Anaplastic Astrocytoma
• Glioblastoma

Interventions

Type	Name	Description
DRUG	β-elemene	β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles

Timeline

• Start date: 2015-04-01
• Primary completion: 2020-04-01
• Completion: 2023-05-01
• First posted: 2015-12-14
• Last updated: 2018-02-23

Locations

1 site across 1 country: China